Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne
Nature Reviews Endocrinology (2017) Vol. 14, Iss. 2, pp. 99-114
Closed Access | Times Cited: 357

Showing 26-50 of 357 citing articles:

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yao Yu, Jingjing Cai, Zhi‐Gang She, et al.
Advanced Science (2018) Vol. 6, Iss. 4
Open Access | Times Cited: 149
Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
J.A. Del Campo, Rocío Gallego‐Durán, Paloma Gallego, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 3, pp. 911-911
Open Access | Times Cited: 135
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, S. Kahl, Kalliopi Pafili, et al.
Metabolism (2020) Vol. 111, pp. 154299-154299
Open Access | Times Cited: 131
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 328-348
Open Access | Times Cited: 130
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 129
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Marieke de Vries, Jan Westerink, Karin Kaasjager, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 12, pp. 3842-3853
Open Access | Times Cited: 113
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, et al.
Metabolites (2020) Vol. 11, Iss. 1, pp. 22-22
Open Access | Times Cited: 102
Ellagic Acid Alleviates Hepatic Oxidative Stress and Insulin Resistance in Diabetic Female Rats
S.A. Polce, Cameron Burke, Lucas Martins França, et al.
Nutrients (2018) Vol. 10, Iss. 5, pp. 531-531
Open Access | Times Cited: 96
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 93
Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events
Jie Xu, Liye Dai, Yijun Zhang, et al.
Stroke (2020) Vol. 52, Iss. 1, pp. 103-110
Open Access | Times Cited: 79
Enzymatic enhancing of triplet–triplet annihilation upconversion by breaking oxygen quenching for background-free biological sensing
Ling Huang, Timmy Le, Kai Huang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 76
Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
Sara Della Torre
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 75
Porcine models for studying complications and organ crosstalk in diabetes mellitus
Simone Renner, Andreas Blutke, Sebastian Clauß, et al.
Cell and Tissue Research (2020) Vol. 380, Iss. 2, pp. 341-378
Closed Access | Times Cited: 74
METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease
Zishan Peng, Yingying Gong, Xuejie Wang, et al.
Molecular Therapy (2021) Vol. 30, Iss. 2, pp. 932-946
Open Access | Times Cited: 73
The adolescent with obesity: what perspectives for treatment?
Antonio Nicolucci, Claudio Maffeis
˜The œItalian Journal of Pediatrics/Italian journal of pediatrics (2022) Vol. 48, Iss. 1
Open Access | Times Cited: 66
Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Qiong Wei, Xinyue Xu, Li Guo, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 65
Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study
Susan F. Martin, Elena P. Sorokin, E. Louise Thomas, et al.
Diabetes Care (2022) Vol. 45, Iss. 2, pp. 460-468
Open Access | Times Cited: 48
Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation
So Yeong Cheon, Juhyun Song
Cell & Bioscience (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 34
Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases
Bedair Dewidar, Lucia Mastrototaro, Cornelia Englisch, et al.
EBioMedicine (2023) Vol. 94, pp. 104714-104714
Open Access | Times Cited: 25
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
Yunpeng Gu, Lei Sun, Wei Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 23
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
Eugene Han, Kyungdo Han, Yong‐ho Lee, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 3, pp. 347-355
Open Access | Times Cited: 22
Self‐Tandem Bio‐Heterojunctions Empower Orthopedic Implants with Amplified Chemo‐Photodynamic Anti‐Pathogenic Therapy and Boosted Diabetic Osseointegration
Rui Shu, Jiamin Sun, Bin Li, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 27
Closed Access | Times Cited: 21
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 13
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
David R. Riley, Theresa Hydes, Gema Hernadez, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2538-2550
Open Access | Times Cited: 9

Scroll to top